Biofrontera (BFRI) Cash from Operations Growth (1y) (2021 - 2025)
Biofrontera (BFRI) Cash from Operations Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 425.00% |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn | -141.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -141.50% |
| Sep 30, 2025 | -201.59% |
| Jun 30, 2025 | 35.03% |
| Mar 31, 2025 | -24.76% |
| Dec 31, 2024 | 88.72% |
| Sep 30, 2024 | 38.15% |
| Jun 30, 2024 | 53.93% |
| Mar 31, 2024 | 10.81% |
| Dec 31, 2023 | -6.82% |
| Sep 30, 2023 | 65.69% |
| Jun 30, 2023 | -9,215.04% |
| Mar 31, 2023 | -76.19% |
| Dec 31, 2022 | 60.48% |
| Sep 30, 2022 | -396.06% |
| Jun 30, 2022 | 110.20% |
| Mar 31, 2022 | 38.24% |
| Dec 31, 2021 | -2,925.94% |